[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"article-gut-bacteria-produced-sugars-the-hidden-trigger-behind-als-and-frontotemporal-dementia-en":3,"ArticleBody_MTUn7PU55zN4kIbNW9kGTlNRLubZLQDjCx4DXvMdhPw":189},{"article":4,"relatedArticles":167,"locale":66},{"id":5,"title":6,"slug":7,"content":8,"htmlContent":9,"excerpt":10,"category":11,"tags":12,"metaDescription":10,"wordCount":13,"readingTime":14,"publishedAt":15,"sources":16,"sourceCoverage":58,"transparency":60,"seo":63,"language":66,"featuredImage":67,"featuredImageCredit":68,"isFreeGeneration":72,"niche":73,"geoTakeaways":77,"geoFaq":86,"entities":96},"69dd33271bfde9ce63ff8576","Gut Bacteria-Produced Sugars: The Hidden Trigger Behind ALS and Frontotemporal Dementia","gut-bacteria-produced-sugars-the-hidden-trigger-behind-als-and-frontotemporal-dementia","## From Gut to Brain: How Bacterial Sugars Drive ALS and Frontotemporal Dementia  \n\nAmyotrophic lateral sclerosis (ALS) rapidly destroys motor neurons, progressing from weakness to paralysis and loss of independent breathing.[2][5] [Frontotemporal dementia](https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FFrontotemporal_dementia) (FTD) mainly damages frontal and temporal lobes, causing major changes in personality, decision‑making, behavior, and language, often in midlife.[3][5]  \n\nMost ALS and FTD cases lack a single clear cause, despite known roles for genes, environment, and head injury.[4][5]  \n\nA new *Cell Reports* study adds the gut microbiome: certain intestinal bacteria produce abnormal, inflammatory glycogen—a storage sugar—that acts as a “danger signal” to the immune system.[3][4][5] This immune activation appears capable of injuring neurons and speeding brain degeneration in ALS and FTD.[1][3][4]  \n\n📊 **Data snapshot**  \n- Study: 23 people with ALS or FTD  \n- ~70% had very high levels of inflammatory glycogen in the gut[1][3][5]  \n- In people without these conditions, only about one‑third showed similarly high levels[1][3]  \n\nThis may explain why two people with the same ALS\u002FFTD‑linked mutation can have different outcomes: disease may emerge mainly in those whose guts are dominated by glycogen‑producing microbes.[3][4][5]  \n\nThese findings fit into the broader “gut–brain axis” field, which examines how microbes and their products influence brain inflammation, cognition, and dementia risk.[4][7] In Alzheimer’s disease, microbiome shifts can alter brain immune activity and may affect how fast memory declines.[7]  \n\n💡 **Key takeaway**  \n- The gut is an active player: microbial sugars from the intestine can send inflammatory signals that may help determine who develops ALS or FTD.[1][3][4]  \n\nPatients and caregivers increasingly describe gut problems—bloating, irregular stools—around the time brain symptoms appear, reinforcing questions about intestinal health and neurodegeneration.  \n\n## The Molecular Chain Reaction: From Gut Glycogen to Neuron Death  \n\nResearchers propose a stepwise chain from gut to brain:[3][4][5]  \n\n1. **Overgrowth of certain gut microbes** → production of unusual, inflammatory glycogen.  \n2. **Glycogen molecules or breakdown products cross or signal beyond the gut lining.**[3][4]  \n3. **[Immune system](https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FImmune_system) detects these bacterial sugars as threats**, triggering inflammatory pathways.[1][3]  \n4. **Activated immune cells and mediators damage vulnerable neurons**, especially motor neurons and cells in frontal and temporal lobes.[3][4][5]  \n\n⚠️ **Key point**  \n- This does not replace genetic risk; it shows how microbial signals can “push” a susceptible brain toward disease.[3][5]  \n\nThe model is especially relevant to people with inherited susceptibility, such as carriers of the [C9orf72 mutation](https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FC9orf72), the most common genetic cause of ALS and FTD.[5] For them, inflammatory bacterial glycogen may be one environmental trigger that converts silent risk into active disease.[3][4][5]  \n\nTo support this idea, investigators examined:[2][3][4]  \n\n- **Gut bacterial communities**  \n- **Chemical forms of glycogen** in stool  \n- **Immune activation markers**, locally and systemically  \n\nThey found:  \n- Elevated inflammatory glycogen strongly correlated with ALS or FTD diagnosis.[1][3][5]  \n- In experimental models, exposing immune cells to these sugars was enough to provoke responses that can harm neurons.[3][4][6]  \n\n💡 **Key takeaway**  \n- Converging patient data, biochemistry, and mechanistic experiments suggest inflammatory bacterial glycogen is unlikely to be a harmless bystander.[2][3][4]  \n\nHowever, the study is small (23 patients) and focused on a specific population. Larger, more diverse cohorts must confirm how generalizable these results are and clarify timing—whether microbial changes precede, accompany, or follow early neurodegeneration.[1][3][4]  \n\n## Future Treatments: Targeting Gut Bacteria Sugars to Protect the Brain  \n\nBy identifying harmful bacterial glycogen as a possible driver of brain damage, this work opens new therapeutic options.[2][5][6] Future strategies may complement brain‑directed treatments by acting in the gut:  \n\n- Suppress or replace glycogen‑producing bacteria  \n- Block microbial enzymes that synthesize inflammatory glycogen  \n- Chemically degrade or neutralize the sugars before they trigger immunity[3][4][5]  \n\nIn experimental systems, blocking immune activation by these sugars reduced brain damage and extended lifespan.[5][6] This suggests:[3][5][6]  \n\n- **New drugs** could break down harmful glycogen in the intestine  \n- **Microbiome‑based therapies** (e.g., targeted probiotics or bacteriophages) might remove culprit microbes  \n- **Precision interventions** could be offered to ALS\u002FFTD patients identified as high‑glycogen “responders” via future biomarkers  \n\n⚡ **Future horizon**  \n- [Clinical trials](https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FClinical_trial) testing whether degrading these sugars can slow ALS\u002FFTD progression could begin within a few years.[3][6]  \n\nCurrently:[2][5]  \n\n- No routine clinical tests measure gut glycogen levels  \n- No approved therapies directly target this pathway  \n\nEven so, the research supports a future in which microbiome profiling could help:[3][5][6]  \n\n- Refine ALS\u002FFTD risk estimates in high‑genetic‑risk families  \n- Personalize treatment choices and trial enrollment  \n- Potentially slow or prevent neurodegeneration when combined with standard neurologic care  \n\n## Conclusion: Watching the Gut–Brain Frontier  \n\n[Inflammatory glycogen](https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FGlycogen_storage_disease_type_I) made by gut bacteria offers a compelling way to link microbes, immunity, and neuron loss in ALS and FTD, and it points toward gut‑focused strategies to limit brain damage.[1][3][5]  \n\nPatients, caregivers, and clinicians may wish to follow emerging gut–brain research, ask specialists about relevant clinical trials, and consider how future microbiome‑based tools might complement—never replace—current ALS and dementia treatments.[2][5][6] Always discuss any concerns or possible interventions with your healthcare provider before changing treatment or diet.","\u003Ch2>From Gut to Brain: How Bacterial Sugars Drive ALS and Frontotemporal Dementia\u003C\u002Fh2>\n\u003Cp>Amyotrophic lateral sclerosis (ALS) rapidly destroys motor neurons, progressing from weakness to paralysis and loss of independent breathing.\u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa>\u003Ca href=\"#source-5\" class=\"citation-link\" title=\"View source [5]\">[5]\u003C\u002Fa> \u003Ca href=\"https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FFrontotemporal_dementia\" class=\"wiki-link\" target=\"_blank\" rel=\"noopener\">Frontotemporal dementia\u003C\u002Fa> (FTD) mainly damages frontal and temporal lobes, causing major changes in personality, decision‑making, behavior, and language, often in midlife.\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-5\" class=\"citation-link\" title=\"View source [5]\">[5]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>Most ALS and FTD cases lack a single clear cause, despite known roles for genes, environment, and head injury.\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003Ca href=\"#source-5\" class=\"citation-link\" title=\"View source [5]\">[5]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>A new \u003Cem>Cell Reports\u003C\u002Fem> study adds the gut microbiome: certain intestinal bacteria produce abnormal, inflammatory glycogen—a storage sugar—that acts as a “danger signal” to the immune system.\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003Ca href=\"#source-5\" class=\"citation-link\" title=\"View source [5]\">[5]\u003C\u002Fa> This immune activation appears capable of injuring neurons and speeding brain degeneration in ALS and FTD.\u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>📊 \u003Cstrong>Data snapshot\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cul>\n\u003Cli>Study: 23 people with ALS or FTD\u003C\u002Fli>\n\u003Cli>~70% had very high levels of inflammatory glycogen in the gut\u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-5\" class=\"citation-link\" title=\"View source [5]\">[5]\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli>In people without these conditions, only about one‑third showed similarly high levels\u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>This may explain why two people with the same ALS\u002FFTD‑linked mutation can have different outcomes: disease may emerge mainly in those whose guts are dominated by glycogen‑producing microbes.\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003Ca href=\"#source-5\" class=\"citation-link\" title=\"View source [5]\">[5]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>These findings fit into the broader “gut–brain axis” field, which examines how microbes and their products influence brain inflammation, cognition, and dementia risk.\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003Ca href=\"#source-7\" class=\"citation-link\" title=\"View source [7]\">[7]\u003C\u002Fa> In Alzheimer’s disease, microbiome shifts can alter brain immune activity and may affect how fast memory declines.\u003Ca href=\"#source-7\" class=\"citation-link\" title=\"View source [7]\">[7]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>💡 \u003Cstrong>Key takeaway\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cul>\n\u003Cli>The gut is an active player: microbial sugars from the intestine can send inflammatory signals that may help determine who develops ALS or FTD.\u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>Patients and caregivers increasingly describe gut problems—bloating, irregular stools—around the time brain symptoms appear, reinforcing questions about intestinal health and neurodegeneration.\u003C\u002Fp>\n\u003Ch2>The Molecular Chain Reaction: From Gut Glycogen to Neuron Death\u003C\u002Fh2>\n\u003Cp>Researchers propose a stepwise chain from gut to brain:\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003Ca href=\"#source-5\" class=\"citation-link\" title=\"View source [5]\">[5]\u003C\u002Fa>\u003C\u002Fp>\n\u003Col>\n\u003Cli>\u003Cstrong>Overgrowth of certain gut microbes\u003C\u002Fstrong> → production of unusual, inflammatory glycogen.\u003C\u002Fli>\n\u003Cli>\u003Cstrong>Glycogen molecules or breakdown products cross or signal beyond the gut lining.\u003C\u002Fstrong>\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli>\u003Cstrong>\u003Ca href=\"https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FImmune_system\" class=\"wiki-link\" target=\"_blank\" rel=\"noopener\">Immune system\u003C\u002Fa> detects these bacterial sugars as threats\u003C\u002Fstrong>, triggering inflammatory pathways.\u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli>\u003Cstrong>Activated immune cells and mediators damage vulnerable neurons\u003C\u002Fstrong>, especially motor neurons and cells in frontal and temporal lobes.\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003Ca href=\"#source-5\" class=\"citation-link\" title=\"View source [5]\">[5]\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Fol>\n\u003Cp>⚠️ \u003Cstrong>Key point\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cul>\n\u003Cli>This does not replace genetic risk; it shows how microbial signals can “push” a susceptible brain toward disease.\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-5\" class=\"citation-link\" title=\"View source [5]\">[5]\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>The model is especially relevant to people with inherited susceptibility, such as carriers of the \u003Ca href=\"https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FC9orf72\" class=\"wiki-link\" target=\"_blank\" rel=\"noopener\">C9orf72 mutation\u003C\u002Fa>, the most common genetic cause of ALS and FTD.\u003Ca href=\"#source-5\" class=\"citation-link\" title=\"View source [5]\">[5]\u003C\u002Fa> For them, inflammatory bacterial glycogen may be one environmental trigger that converts silent risk into active disease.\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003Ca href=\"#source-5\" class=\"citation-link\" title=\"View source [5]\">[5]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>To support this idea, investigators examined:\u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa>\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cul>\n\u003Cli>\u003Cstrong>Gut bacterial communities\u003C\u002Fstrong>\u003C\u002Fli>\n\u003Cli>\u003Cstrong>Chemical forms of glycogen\u003C\u002Fstrong> in stool\u003C\u002Fli>\n\u003Cli>\u003Cstrong>Immune activation markers\u003C\u002Fstrong>, locally and systemically\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>They found:\u003C\u002Fp>\n\u003Cul>\n\u003Cli>Elevated inflammatory glycogen strongly correlated with ALS or FTD diagnosis.\u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-5\" class=\"citation-link\" title=\"View source [5]\">[5]\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli>In experimental models, exposing immune cells to these sugars was enough to provoke responses that can harm neurons.\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>💡 \u003Cstrong>Key takeaway\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cul>\n\u003Cli>Converging patient data, biochemistry, and mechanistic experiments suggest inflammatory bacterial glycogen is unlikely to be a harmless bystander.\u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa>\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>However, the study is small (23 patients) and focused on a specific population. Larger, more diverse cohorts must confirm how generalizable these results are and clarify timing—whether microbial changes precede, accompany, or follow early neurodegeneration.\u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003C\u002Fp>\n\u003Ch2>Future Treatments: Targeting Gut Bacteria Sugars to Protect the Brain\u003C\u002Fh2>\n\u003Cp>By identifying harmful bacterial glycogen as a possible driver of brain damage, this work opens new therapeutic options.\u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa>\u003Ca href=\"#source-5\" class=\"citation-link\" title=\"View source [5]\">[5]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa> Future strategies may complement brain‑directed treatments by acting in the gut:\u003C\u002Fp>\n\u003Cul>\n\u003Cli>Suppress or replace glycogen‑producing bacteria\u003C\u002Fli>\n\u003Cli>Block microbial enzymes that synthesize inflammatory glycogen\u003C\u002Fli>\n\u003Cli>Chemically degrade or neutralize the sugars before they trigger immunity\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003Ca href=\"#source-5\" class=\"citation-link\" title=\"View source [5]\">[5]\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>In experimental systems, blocking immune activation by these sugars reduced brain damage and extended lifespan.\u003Ca href=\"#source-5\" class=\"citation-link\" title=\"View source [5]\">[5]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa> This suggests:\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-5\" class=\"citation-link\" title=\"View source [5]\">[5]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cul>\n\u003Cli>\u003Cstrong>New drugs\u003C\u002Fstrong> could break down harmful glycogen in the intestine\u003C\u002Fli>\n\u003Cli>\u003Cstrong>Microbiome‑based therapies\u003C\u002Fstrong> (e.g., targeted probiotics or bacteriophages) might remove culprit microbes\u003C\u002Fli>\n\u003Cli>\u003Cstrong>Precision interventions\u003C\u002Fstrong> could be offered to ALS\u002FFTD patients identified as high‑glycogen “responders” via future biomarkers\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>⚡ \u003Cstrong>Future horizon\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cul>\n\u003Cli>\u003Ca href=\"https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FClinical_trial\" class=\"wiki-link\" target=\"_blank\" rel=\"noopener\">Clinical trials\u003C\u002Fa> testing whether degrading these sugars can slow ALS\u002FFTD progression could begin within a few years.\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>Currently:\u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa>\u003Ca href=\"#source-5\" class=\"citation-link\" title=\"View source [5]\">[5]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cul>\n\u003Cli>No routine clinical tests measure gut glycogen levels\u003C\u002Fli>\n\u003Cli>No approved therapies directly target this pathway\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>Even so, the research supports a future in which microbiome profiling could help:\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-5\" class=\"citation-link\" title=\"View source [5]\">[5]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cul>\n\u003Cli>Refine ALS\u002FFTD risk estimates in high‑genetic‑risk families\u003C\u002Fli>\n\u003Cli>Personalize treatment choices and trial enrollment\u003C\u002Fli>\n\u003Cli>Potentially slow or prevent neurodegeneration when combined with standard neurologic care\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Ch2>Conclusion: Watching the Gut–Brain Frontier\u003C\u002Fh2>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FGlycogen_storage_disease_type_I\" class=\"wiki-link\" target=\"_blank\" rel=\"noopener\">Inflammatory glycogen\u003C\u002Fa> made by gut bacteria offers a compelling way to link microbes, immunity, and neuron loss in ALS and FTD, and it points toward gut‑focused strategies to limit brain damage.\u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-5\" class=\"citation-link\" title=\"View source [5]\">[5]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>Patients, caregivers, and clinicians may wish to follow emerging gut–brain research, ask specialists about relevant clinical trials, and consider how future microbiome‑based tools might complement—never replace—current ALS and dementia treatments.\u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa>\u003Ca href=\"#source-5\" class=\"citation-link\" title=\"View source [5]\">[5]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa> Always discuss any concerns or possible interventions with your healthcare provider before changing treatment or diet.\u003C\u002Fp>\n","From Gut to Brain: How Bacterial Sugars Drive ALS and Frontotemporal Dementia  \n\nAmyotrophic lateral sclerosis (ALS) rapidly destroys motor neurons, progressing from weakness to paralysis and loss of...","trend-radar",[],804,4,"2026-04-13T18:24:39.126Z",[17,22,26,30,34,38,42,46,50,54],{"title":18,"url":19,"summary":20,"type":21},"Gut Bacteria Linked to ALS and FTD Brain Deterioration","https:\u002F\u002Fwww.linkedin.com\u002Fposts\u002Ferwinloh_gutbrain-link-identified-in-dementia-and-activity-7426912616079466496-lOK3","By Professor Erwin Loh • 2mo\n\nGut–Brain Link Identified in Dementia and ALS Researchers have identified a link between gut bacteria and brain deterioration in ALS and frontotemporal dementia. Study fo...","kb",{"title":23,"url":24,"summary":25,"type":21},"Gut Bacteria Discovery Could Change How Doctors Treat ALS and Dementia","https:\u002F\u002Fscitechdaily.com\u002Fgut-bacteria-discovery-could-change-how-doctors-treat-als-and-dementia\u002F","Gut Bacteria Discovery Could Change How Doctors Treat ALS and Dementia\n\nBy Case Western Reserve University March 16, 2026 4 Mins Read\n\nResearchers have uncovered a surprising connection between gut ba...",{"title":27,"url":28,"summary":29,"type":21},"A Sugar Made by Gut Bacteria Can Drive Neurodegeneration","https:\u002F\u002Fwww.labroots.com\u002Ftrending\u002Fmicrobiology\u002F30193\u002Fsugar-gut-bacteria-drive-neurodegeneration?srsltid=AfmBOopEmKe4XDhQQQormr2_5V2CDSKIZrBhuXBcCP_CFUMHjSIU1VQI","WRITTEN BY: Carmen Leitch\n\nResearchers have uncovered a novel connection between two neurodegenerative disorders. This research, which was published in Cell Reports, found that gut bacteria are linked...",{"title":31,"url":32,"summary":33,"type":21},"Scientists discover hidden gut trigger behind ALS and dementia","https:\u002F\u002Fwww.sciencedaily.com\u002Freleases\u002F2026\u002F04\u002F260408225944.htm","Researchers have uncovered a finding that could reshape how doctors approach two of the most devastating brain disorders. Their work points to an unexpected player in disease progression: gut bacteria...",{"title":35,"url":36,"summary":37,"type":21},"New gut-brain discovery offers hope for treating ALS and dementia","https:\u002F\u002Fcase.edu\u002Fnews\u002Fnew-gut-brain-discovery-offers-hope-treating-als-and-dementia","A significant discovery by Case Western Reserve University researchers could change how doctors treat two of the most devastating neurodegenerative diseases.\n\nThe team identified a link between gut ba...",{"title":39,"url":40,"summary":41,"type":21},"What if the key to treating ALS and dementia starts in the gut?","https:\u002F\u002Fwww.facebook.com\u002Fcasewesternreserve\u002Fposts\u002Fwhat-if-the-key-to-treating-als-and-dementia-starts-in-the-gutcwru-researchers-i\u002F1359502592872914\u002F","What if the key to treating ALS and dementia starts in the gut?\n\nCWRU researchers identified a bacterial sugar that triggers brain damage and a way to stop it. Learn how this breakthrough could transf...",{"title":43,"url":44,"summary":45,"type":21},"Alzheimer’s and the Gut-Brain Superhighway","https:\u002F\u002Fwww.pbs.org\u002Fvideo\u002Falzheimers-and-the-gut-brain-superhighway-ejmfxh\u002F","Alzheimer’s and the Gut-Brain Superhighway\n\nSpecial | 57m 42s Video has Closed Captions | CC\n\nFederico Rey and Barbara Bendlin discuss how the gut microbiome impacts brain health.\n\nFederico Rey and Ba...",{"title":47,"url":48,"summary":49,"type":21},"One in 10 people may have resistance to GLP-1 diabetes drugs","https:\u002F\u002Fmed.stanford.edu\u002Fnews\u002Fall-news\u002F2026\u002F04\u002Fglp-1-diabetes.html","New research suggests that certain genetic variants can decrease the ability of GLP-1 diabetes drugs to regulate blood sugar — a mysterious phenomenon known as GLP-1 resistance.\n\nMore than a quarter o...",{"title":51,"url":52,"summary":53,"type":21},"Two genetic variants linked to the effects of GLP-1 drugs for obesity","https:\u002F\u002Fsciencemediacentre.es\u002Fen\u002Ftwo-genetic-variants-linked-effects-glp-1-drugs-obesity","Two genetic variants linked to the effects of GLP-1 drugs for obesity\n\nGLP-1 medicines for the treatment of obesity show considerable variability between individuals. Using data from 23andMe, scientis...",{"title":55,"url":56,"summary":57,"type":21},"GLP-1 drugs like Ozempic don’t work for everyone. Genetic variants offer new clues","https:\u002F\u002Fwww.scientificamerican.com\u002Farticle\u002Fhow-well-glp-1-weight-loss-drugs-work-may-depend-on-your-genetics\u002F","GLP-1 Drugs\n\nOf all the millions of people who have tried weight-loss drugs such as Wegovy and Zepbound, nearly one in four people don’t respond to treatment. They lose little weight, or none at all, ...",{"totalSources":59},10,{"generationDuration":61,"kbQueriesCount":59,"confidenceScore":62,"sourcesCount":59},151497,100,{"metaTitle":64,"metaDescription":65},"Gut Bacteria Sugars Trigger ALS and FTD Risk Insights","Discover how gut bacterial sugars trigger immune inflammation linked to ALS and FTD. Read new research and learn implications for diagnosis, prevention.","en","https:\u002F\u002Fimages.unsplash.com\u002Fphoto-1684844027899-63f6d470b9f3?ixid=M3w4OTczNDl8MHwxfHNlYXJjaHwxfHxndXQlMjBiYWN0ZXJpYSUyMHByb2R1Y2VkJTIwc3VnYXJzfGVufDF8MHx8fDE3NzYxMDQyMzF8MA&ixlib=rb-4.1.0&w=1200&h=630&fit=crop&crop=entropy&auto=format,compress&q=60",{"photographerName":69,"photographerUrl":70,"unsplashUrl":71},"masakazu sasaki","https:\u002F\u002Funsplash.com\u002F@masakz?utm_source=coreprose&utm_medium=referral","https:\u002F\u002Funsplash.com\u002Fphotos\u002Fa-close-up-of-a-tray-of-food-on-a-table-BEtjbgwEGwg?utm_source=coreprose&utm_medium=referral",true,{"key":74,"name":75,"nameEn":76},"sante","Santé & Médecine","Health & Medicine",[78,80,82,84],{"text":79},"A Cell Reports study found that ~70% of 23 people with ALS or FTD had very high levels of inflammatory bacterial glycogen in the gut, versus about one‑third of controls.",{"text":81},"Elevated inflammatory glycogen strongly correlated with ALS\u002FFTD diagnosis and, in experimental models, exposure to these sugars activated immune responses that damaged neurons and shortened survival.",{"text":83},"The study involved only 23 patients and is not definitive, but blocking glycogen‑driven immune activation reduced brain damage and extended lifespan in models, supporting causality.",{"text":85},"No routine clinical tests or approved therapies currently measure or target gut glycogen; microbiome‑based interventions and glycogen‑degrading drugs are proposed next steps and candidate trial targets.",[87,90,93],{"question":88,"answer":89},"How strong is the evidence that gut bacterial glycogen causes or accelerates ALS and FTD?","The evidence is suggestive but not conclusive. Direct human data come from a small cohort (23 patients) showing a strong association between high levels of inflammatory bacterial glycogen and ALS\u002FFTD, and complementary biochemical and immunological analyses linked those sugars to immune activation. Mechanistic support comes from experimental models where exposing immune cells to the bacterial glycogen provoked neurotoxic inflammatory responses and where interventions that blocked this pathway reduced neuronal damage and extended survival. Large, diverse longitudinal human cohorts and interventional trials are required to establish causation and timing.",{"question":91,"answer":92},"What specific treatments could target bacterial glycogen to protect the brain?","Several gut‑directed strategies are plausible and are supported by preclinical data. Approaches include selectively suppressing or replacing glycogen‑producing microbes (targeted antibiotics, bacteriophages, or probiotics), developing small‑molecule inhibitors of microbial enzymes that synthesize inflammatory glycogen, and administering enzymes or binding agents that chemically degrade or neutralize glycogen before it triggers immunity. In experimental systems, interventions that blocked glycogen‑induced immune activation reduced brain injury and extended lifespan, making these strategies realistic candidates for early clinical trials within a few years if safety and efficacy are demonstrated.",{"question":94,"answer":95},"Should patients with ALS, FTD, or genetic risk change their diet, take probiotics, or pursue microbiome testing now?","Patients should not make major changes based solely on this single small study without clinician guidance. No validated clinical tests currently measure gut glycogen levels, and no approved therapies target this pathway yet. Reasonable actions include discussing GI symptoms with your neurologist, considering referral to a gastroenterologist if problems are significant, and asking about relevant clinical trials. Any probiotic, antibiotic, or dietary intervention can alter gut ecology and immune responses and should be undertaken only with medical oversight and ideally within a research protocol.",[97,103,106,111,116,120,125,130,135,141,145,150,153,158,163],{"id":98,"name":99,"type":100,"confidence":101,"wikipediaUrl":102},"69d19b884eea09eba3dfe8f2","Gut microbiome","concept",0.98,null,{"id":104,"name":105,"type":100,"confidence":101,"wikipediaUrl":102},"69dd3511dc9b1294374468ad","Amyotrophic lateral sclerosis",{"id":107,"name":108,"type":100,"confidence":109,"wikipediaUrl":110},"69dd3512dc9b1294374468b4","C9orf72 mutation",0.93,"https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FC9orf72",{"id":112,"name":113,"type":100,"confidence":114,"wikipediaUrl":115},"69dd3512dc9b1294374468b2","Frontal and temporal lobes",0.95,"https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FFrontal_lobe",{"id":117,"name":118,"type":100,"confidence":114,"wikipediaUrl":119},"69dd3512dc9b1294374468b3","Immune system","https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FImmune_system",{"id":121,"name":122,"type":100,"confidence":123,"wikipediaUrl":124},"69dd3511dc9b1294374468af","Inflammatory glycogen",0.94,"https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FGlycogen_storage_disease_type_I",{"id":126,"name":127,"type":100,"confidence":128,"wikipediaUrl":129},"69dd3512dc9b1294374468b1","Motor neurons",0.96,"https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FMotor_neuron",{"id":131,"name":132,"type":100,"confidence":133,"wikipediaUrl":134},"69dd3511dc9b1294374468ae","Frontotemporal dementia",0.97,"https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FFrontotemporal_dementia",{"id":136,"name":137,"type":138,"confidence":139,"wikipediaUrl":140},"69dd3512dc9b1294374468b0","Cell Reports study","event",0.9,"https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FScientific_Reports",{"id":142,"name":143,"type":138,"confidence":139,"wikipediaUrl":144},"69dd3513dc9b1294374468b8","Clinical trials","https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FClinical_trial",{"id":146,"name":147,"type":148,"confidence":149,"wikipediaUrl":102},"69dd3513dc9b1294374468b9","Patients with ALS or FTD (study cohort)","other",0.92,{"id":151,"name":152,"type":148,"confidence":139,"wikipediaUrl":102},"69dd3513dc9b1294374468ba","Controls (people without ALS\u002FFTD)",{"id":154,"name":155,"type":156,"confidence":157,"wikipediaUrl":102},"69dd3512dc9b1294374468b5","Microbiome-based therapies","product",0.88,{"id":159,"name":160,"type":156,"confidence":161,"wikipediaUrl":162},"69dd3512dc9b1294374468b6","Targeted probiotics",0.86,"https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FProbiotic",{"id":164,"name":165,"type":156,"confidence":161,"wikipediaUrl":166},"69dd3512dc9b1294374468b7","Bacteriophages","https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FBacteriophage",[168,175,182],{"id":169,"title":170,"slug":171,"excerpt":172,"category":11,"featuredImage":173,"publishedAt":174},"69df07d1461a4d3bb7139375","How Zeaxanthin Supercharges T Cells and Could Transform Cancer Immunotherapy","how-zeaxanthin-supercharges-t-cells-and-could-transform-cancer-immunotherapy","From eye vitamin to immune ally: what zeaxanthin is and why it matters\n\nZeaxanthin is a yellow‑orange carotenoid in plants, especially leafy greens like spinach and kale, and yellow vegetables such as...","https:\u002F\u002Fimages.unsplash.com\u002Fphoto-1666402667406-df3723f1b777?ixid=M3w4OTczNDl8MHwxfHNlYXJjaHwxfHx6ZWF4YW50aGluJTIwbnV0cmllbnQlMjBzdHJlbmd0aGVucyUyMGNlbGxzfGVufDF8MHx8fDE3NzYyMjQyMDl8MA&ixlib=rb-4.1.0&w=1200&h=630&fit=crop&crop=entropy&auto=format,compress&q=60","2026-04-15T03:44:01.558Z",{"id":176,"title":177,"slug":178,"excerpt":179,"category":11,"featuredImage":180,"publishedAt":181},"69d48127fc9a83011893c2c3","How Digital Heart Twins Guided Successful VT Ablation in 10 Patients","how-digital-heart-twins-guided-successful-vt-ablation-in-10-patients","From Ventricular Tachycardia to Digital Heart Twins: Why This Trial Matters\n\nVentricular tachycardia (VT) is a rapid rhythm from the heart’s lower chambers that can degenerate into ventricular fibrill...","https:\u002F\u002Fimages.unsplash.com\u002Fphoto-1739185253617-4fdc1cd3d62a?ixid=M3w4OTczNDl8MHwxfHNlYXJjaHwxfHxkaWdpdGFsJTIwaGVhcnQlMjB0d2lucyUyMGd1aWRlZHxlbnwxfDB8fHwxNzc1NTM0Mzc1fDA&ixlib=rb-4.1.0&w=1200&h=630&fit=crop&crop=entropy&auto=format,compress&q=60","2026-04-07T04:07:18.077Z",{"id":183,"title":184,"slug":185,"excerpt":186,"category":11,"featuredImage":187,"publishedAt":188},"69d245a2b3b92dfc3f9f296a","Five-Day Fasting-Mimicking Diet Shows Promise for Crohn’s Disease Relief","five-day-fasting-mimicking-diet-shows-promise-for-crohn-s-disease-relief","For many people with Crohn’s disease, diet feels like a missing treatment piece. A new Stanford-led randomized clinical trial suggests a structured, five-day‑a‑month fasting-mimicking diet (FMD) can i...","https:\u002F\u002Fimages.unsplash.com\u002Fphoto-1767972159709-52936afffdbf?ixid=M3w4OTczNDl8MHwxfHNlYXJjaHwxfHxmaXZlJTIwZGF5JTIwZmFzdGluZyUyMG1pbWlja2luZ3xlbnwxfDB8fHwxNzc1MzQxMzMwfDA&ixlib=rb-4.1.0&w=1200&h=630&fit=crop&crop=entropy&auto=format,compress&q=60","2026-04-05T11:26:13.402Z",["Island",190],{"key":191,"params":192,"result":194},"ArticleBody_MTUn7PU55zN4kIbNW9kGTlNRLubZLQDjCx4DXvMdhPw",{"props":193},"{\"articleId\":\"69dd33271bfde9ce63ff8576\"}",{"head":195},{}]